Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2026)

Rigel Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $54.2 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 10.81% year-over-year to $54.2 million in Q1 2026; TTM through Mar 2026 was $279.9 million, a 53.78% increase from a year earlier, with the FY2025 full-year figure at $274.7 million, up 70.99% from the prior year.
• Gross Profit declined to $54.2 million in Q1 2026 per RIGL's latest filing, from $63.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $97.2 million in Q2 2025 and bottomed at $16.6 million in Q1 2022.
• The 5-year median for Gross Profit is $34.0 million (2024), against an average of $42.2 million.
• Across the five-year window, Gross Profit plunged 79.41% in 2022 and soared 185.54% in 2025, its largest moves.
• Year by year, Gross Profit stood at $50.9 million in 2022, then slumped by 37.17% to $32.0 million in 2023, then soared by 61.89% to $51.8 million in 2024, then increased by 23.24% to $63.8 million in 2025, then fell by 15.09% to $54.2 million in 2026.
• Per Business Quant, the three latest RIGL Gross Profit figures stand at $54.2 million (Q1 2026), $63.8 million (Q4 2025), and $64.7 million (Q3 2025).